Gannet BioChem has acquired Laysan Bio to enhance its capabilities in PEG reagents and bioconjugation, aligning with its strategy to innovate within the life sciences sector.

Information on the Target

Gannet BioChem, based in Huntsville, Alabama, is a prominent specialty Contract Development and Manufacturing Organization (CDMO) backed by the Boston-based private equity firm Ampersand Capital Partners. Recently, the company has expanded its capabilities through the acquisition of Laysan Bio, a life sciences company located in Arab, Alabama. This strategic acquisition enhances Gannet BioChem’s portfolio in activated polymer technologies, particularly in the areas of polyethylene glycol (PEG) reagents and bioconjugation, facilitating greater support for its partners from early development stages to Good Manufacturing Practice (GMP) production.

Laysan Bio, founded nearly two decades ago, has established itself as a reliable supplier of a variety of cataloged, custom, and compliant activated polymer reagents, serving academic institutions, biotechnology firms, and pharmaceutical companies. The company’s strong technical expertise and robust quality assurance frameworks significantly complement Gannet BioChem's existing capabilities, thereby bolstering both companies’ abilities to cater to advanced therapeutic applications, drug delivery systems, and medical device initiatives.

Industry Overview in Alabama

The life sciences industry in Alabama is experiencing robust growth, characterized by an increase in research activities and investments in biotechnology and pharmaceuticals. With institutions like the University of Alabama and world-class research hospitals driving innova